Actually, DewDiligence has it right. Here's the exact quote from MRK's R&D presentation in May.
Next slide. Let me now move on to oncology with our mTOR inhibitor, ridaforolimus -- or MK-8669. Our oncology pipeline, as you know, is relatively young, but it's developing nicely. I'm pleased to say that our mTOR inhibitor is moving along well, and we anticipate filing it for soft tissue sarcoma this year, pending the results of an interim analysis.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.